Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$757.8M
62M shares
52-week range
$7.77 – $32.76
19% from low
Sector
SERVICES-BUSINESS SERVICES, NEC
Exchange
NYSE
CS
Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
www.phreesia.comNo one on the platform currently holds PHR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 13,600 | $309.9K |
| Bridgewater Associatesas of 2025-12-31 | 12,805 | $216.7K |
No one on the platform has traded PHR yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$PHR investors: there is a new case filed against Phreesia for overstating its growth outlook while hiding weaker pharmaceutical marketing commitments in its Network Solutions segment. If you held shares between 2025 and 2026, you can join the case and track recovery here https://11th.com/cases/phreesia-investor-suit
View on StockTwits ↗$INTC 466% already; congrats 🔆🌿🌟 Checkout $PHR and $RXRX; similar or greater potential. Do your DD and get in. All the best.
View on StockTwits ↗$CPRI $MU $ON $MU1588 % already; congrats 🔆🌿🌟 Checkout $PHR and $$TTD; undervalued now, but can easily double or triple from here; for those who are patient. $RXR X, is generational wealth opportunity for longs.
View on StockTwits ↗$PHR Outstanding article that hits the mark on PHR's current state. So if you want to refresh your PHR insights or learn about PHR from scratch, this is a must read. https://everyticker.com/quote/PHR/analysis/phreesia-s-profitability-inflection-meets-6b-payment-opportunity-nasdaq-phr
View on StockTwits ↗$PHR If this holds $10.00, $15.00 could be the new target.
View on StockTwits ↗$PHR my god keep handing out cheapies! thank you thank you
View on StockTwits ↗$PHR no brainer at this price. easy double from here by end of 2026 if operating momentum continues and that's still using a distressed 10x multiple
View on StockTwits ↗$PHR Ouchy. Guess I will be staying away completely. Stock is so weak
View on StockTwits ↗$PHR - Phreesia Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +2041.1% above peer average (29,847 vs 1,394 across 714 peers). PHR flags rising risks from its financing arm’s dependence on securitization capital, higher card network/interchange fees, new restructuring-driven execution and morale challenges, longer and more volatile sales cycles, intensifying AI-driven competition and regulatory burdens, expanding data security/privacy and identity-theft obligations (highlighting a 2024 ConnectOnCall incident), and restrictive covenants in a new securitization program that could constrain liquidity and operations. #HealthcareTechnology #SecuritizationRisks #AICompetition #DataSecurity #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/PHR/10-Q/2026-05-28
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $515M | +7.2% | $0.40 | $0.30–$0.53 | 31.1× | 8 |
| 2028 | $540M | +4.9% | $0.67 | $0.54–$0.93 | 18.6× | 8 |
| 2029 | $558M | +3.3% | $0.77 | $0.66–$0.85 | 16.1× | 4 |
| 2030 | $539M | -3.4% | $0.92 | $0.88–$0.95 | 13.5× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-27 | $0.02 | $0.05 | +150.0% |
| 2026-03-30 | $0.07 | $0.12 | +82.6% |
| 2025-12-08 | $-0.00 | $0.10 | +27877.8% |
| 2025-09-04 | $-0.07 | $0.01 | +114.3% |
| 2025-05-28 | $-0.13 | $-0.07 | +46.2% |
| 2025-03-12 | $-0.19 | $-0.11 | +42.1% |
| 2024-12-09 | $-0.27 | $-0.25 | +7.4% |
| 2024-09-04 | $-0.37 |
| $-0.31 |
| +16.2% |
| $1.6B |
| — |
| NEOGNeogen Corporation | $11.89 | +3.75% | $2.6B | — |
| NVCRNovocure Ltd | $17.38 | -1.19% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry